Related Experiment Video
Updated: Aug 29, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Antithrombotics prescription and adherence among stroke survivors: A systematic review and meta-analysis
Min Yang1, Hang Cheng1, Xia Wang2
1Department of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Insights
Stroke survivors often don't receive recommended antithrombotic drugs, with less than 70% prescribed guideline-based treatments. Good adherence to these crucial medications is only 73%, highlighting a need for improvement in stroke care.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Stroke is a leading cause of long-term disability and mortality worldwide.
- Antithrombotic medications, including anticoagulants and antiplatelets, are crucial for secondary prevention after stroke.
- Suboptimal prescription rates and medication adherence can lead to recurrent stroke events.
Purpose of the Study:
- To investigate the prescription patterns of antithrombotic drugs following stroke.
- To assess medication adherence among stroke survivors taking antithrombotic therapy.
- To identify gaps in guideline-based antithrombotic treatment and adherence.
Main Methods:
- Systematic literature search of MEDLINE and Embase databases (2015-2022).
- Inclusion of 46 studies comprising 453,625 stroke patients.
- Data extraction and quality assessment using the Newcastle-Ottawa scale, with meta-analysis where appropriate.
Main Results:
- Pooled prescription rates for antiplatelets and anticoagulants in atrial fibrillation patients were 62% and 68%, respectively.
- Only 67% of patients received antithrombotic treatment aligned with clinical guidelines.
- Good adherence rates were observed at 78% for antiplatelets, 71% for anticoagulants, and 73% for overall antithrombotics.
Conclusions:
- Less than 70% of stroke patients are prescribed and treated with guideline-recommended antithrombotic medications.
- Overall adherence to antithrombotic therapy among stroke survivors is suboptimal, at 73%.
- Significant improvements are needed in both the prescription and adherence of antithrombotic medications to enhance secondary stroke prevention.
Objectives:
We aimed to investigate the prescription of antithrombotic drugs (including anticoagulants and antiplatelets) and medication adherence after stroke.
Methods:
We performed a systematic literature search across MEDLINE and Embase, from January 1, 2015, to February 17, 2022, to identify studies reporting antithrombotic medications (anticoagulants and antiplatelets) post stroke. Two people independently identified reports to include, extracted data, and assessed the quality of included studies according to the Newcastle-Ottawa scale. Where possible, data were pooled using random-effects meta-analysis.
Results:
We included 453,625 stroke patients from 46 studies. The pooled proportion of prescribed antiplatelets and anticoagulants among patients with atrial fibrillation (AF) was 62% (95% CI: 57%-68%), and 68% (95% CI: 58%-79%), respectively. The pooled proportion of patients who were treated according to the recommendation of guidelines of antithrombotic medications from four studies was 67% (95% CI: 41%-93%). It was reported that 11% (95% CI: 2%-19%) of patients did not receive antithrombotic medications. Good adherence to antiplatelet, anticoagulant, and antithrombotic medications was 78% (95% CI: 67%-89%), 71% (95% CI: 57%-84%), and 73% (95% CI: 59%-86%), respectively.
Conclusion:
In conclusion, we found that less than 70% of patients were prescribed and treated according to the recommended guidelines of antithrombotic medications, and good adherence to antithrombotic medications is only 73%. Prescription rate and good adherence to antithrombotic medications still need to be improved among stroke survivors.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Coronary Artery Disease V: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

